Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss
Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects
of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public …
of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public …
Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …
Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study
R Nahra, T Wang, KM Gadde, J Oscarsson… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes …
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes …
Nonalcoholic fatty liver disease 2020: the state of the disease
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
NAFLD is one of the most important causes of liver disease worldwide and will probably
emerge as the leading cause of end-stage liver disease in the coming decades, with the …
emerge as the leading cause of end-stage liver disease in the coming decades, with the …
MAFLD: A multisystem disease
RM Pipitone, C Ciccioli, G Infantino… - Therapeutic …, 2023 - journals.sagepub.com
Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and
more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and …
more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and …
[PDF][PDF] Modulation of insulin resistance in nonalcoholic fatty liver disease
RS Khan, F Bril, K Cusi, PN Newsome - Hepatology, 2019 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general
population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to …
population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to …
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Key physiological functions of the liver, including glucose and lipid metabolism, become
disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated …
disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated …
Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?
Non-alcoholic fatty liver disease (NAFLD) has become one of the most common forms of
chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD …
chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD …
NAFLD and diabetes mellitus
H Tilg, AR Moschen, M Roden - Nature reviews Gastroenterology & …, 2017 - nature.com
The liver constitutes a key organ in systemic metabolism, contributing substantially to the
development of insulin resistance and type 2 diabetes mellitus (T2DM). The mechanisms …
development of insulin resistance and type 2 diabetes mellitus (T2DM). The mechanisms …